Berenberg initiated coverage of Omega Healthcare (OHI) with a Buy rating and $45 price target Healthcare real estate investment trusts in the U.S. were heavily affected by COVID-19, as capital markets took a more cautious view on the sector due to concerns about the solvency of operators, the analyst tells investors in a research note. However, with interest rates likely to take a downward trajectory, the share prices of healthcare REITs have already started to stabilize, contends the Berenberg. As a results, it expects the capital markets will view the supportive market fundamentals for Omega Healthcare Investors and Global Medical REIT more positively given the demographic development of the companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare price target raised to $45 from $44 at BMO Capital
- Omega Healthcare assumed with an Overweight at Wells Fargo
- Omega Healthcare files automatic mixed securities shelf
- Sabra Health Care price target raised to $18 from $16 at Truist
- Omega Healthcare price target raised to $39 from $33 at Truist
